Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Dec 6;23(23):15369.
doi: 10.3390/ijms232315369.

Genetic Study of Early Onset Parkinson's Disease in Cyprus

Affiliations

Genetic Study of Early Onset Parkinson's Disease in Cyprus

Rana Abu Manneh et al. Int J Mol Sci. .

Abstract

Parkinson's Disease (PD) is a multifactorial neurodegenerative disease characterized by motor and non-motor symptoms. The etiology of PD remains unclear. However, several studies have demonstrated the interplay of genetic, epigenetic, and environmental factors in PD. Early-onset PD (EOPD) is a subgroup of PD diagnosed between the ages of 21 and 50. Population genetic studies have demonstrated great genetic variability amongst EOPD patients. Hence, this study aimed to obtain a genetic landscape of EOPD in the Cypriot population. Greek-Cypriot EOPD patients (n = 48) were screened for variants in the six most common EOPD-associated genes (PINK1, PRKN, FBXO7, SNCA, PLA2G6, and DJ-1). This included DNA sequencing and Multiplex ligation-dependent probe amplification (MLPA). One previously described frameshift variant in PINK1 (NM_032409.3:c.889del) was detected in five patients (10.4%)-the largest number to be detected to date. Copy number variations in the PRKN gene were identified in one homozygous and 3 compound heterozygous patients (8.3%). To date, the pathogenic variants identified in this study have explained the PD phenotype for 18.8% of the EOPD cases. The results of this study may contribute to the genetic screening of EOPD in Cyprus.

Keywords: Greek-Cypriot Parkinson’s patients; early onset Parkinson’s disease (EOPD); genetic investigation.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.

References

    1. Tysnes O.B., Storstein A. Epidemiology of Parkinson’s disease. J. Neural Transm. 2017;124:901–905. doi: 10.1007/s00702-017-1686-y. - DOI - PubMed
    1. Dorsey E.R., Elbaz A., Nichols E., Abd-Allah F., Abdelalim A., Adsuar J.C., Ansha M.G., Brayne C., Choi J.Y.J., Collado-Mateo D., et al. Global, regional, and national burden of Parkinson’s disease, 1990–2016: A systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2018;17:939–953. doi: 10.1016/S1474-4422(18)30295-3. - DOI - PMC - PubMed
    1. Maserejian A.D.N., Vinikoor-Imler L. Estimation of the 2020 Global Population of Parkinson’s Disease (PD) [(accessed on 14 September 2021)];Mov. Disord. 2020 35 Available online: https://www.mdsabstracts.org/abstract/estimation-of-the-2020-global-popu...
    1. Schrag A., Schott J.M. Epidemiological, clinical, and genetic characteristics of early-onset parkinsonism. Lancet Neurol. 2006;5:355–363. doi: 10.1016/S1474-4422(06)70411-2. - DOI - PubMed
    1. Milanowski Ł.M., Lindemann J.A., Hoffman-Zacharska D., Soto-Beasley A.I., Barcikowska M., Boczarska-Jedynak M., Deutschlander A., Kłodowska G., Dulski J., Fedoryshyn L., et al. Frequency of Mutations in PRKN, PINK1, and DJ1 in Patients with Early-Onset Parkinson Disease from Neighboring Countries in Central Europe. Park. Relat. Disord. 2021;86:48. doi: 10.1016/j.parkreldis.2021.03.026. - DOI - PMC - PubMed

Substances

Grants and funding